| Dr Roger A Coleman, MD | |
|
3333 Riverbend Drive, Springfield, OR 97477-8800 | |
| (541) 222-3154 | |
| (541) 222-3359 |
| Full Name | Dr Roger A Coleman |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 20 Years |
| Location | 3333 Riverbend Drive, Springfield, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194928739 | NPI | - | NPPES |
| MD265999 | Other | OR | STATE MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD26599 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sacred Heart Medical Center - Riverbend | Springfield, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Anesthesia Physicians Pc | 3274420138 | 76 |
News Archive
Building upon previous work, researchers at the Icahn School of Medicine at Mount Sinai identified cells in the embryos of mice that are precursors to blood stem cells or hematopoietic stem/progenitor cells.
A cross-institutional research group has revealed for the first time in the world that infants with symptomatic congenital cytomegalovirus (CMV) infection who were treated with a combination of immunoglobulin fetal therapy and neonatal therapy with antiviral drugs were less likely to experience the severe aftereffects associated with the infection than those who only received the neonatal therapy.
Oncotarget published "Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis" which reported that microscopic imaging, immunocytochemistry, wound healing assay, caspase-cleaved cytokeratin 18 CytoDeath ELISA assay, immunofluorescence labeling assays for apoptosis, hypoxia, Western Blotting, Tunnel assay, measurement of 5-HT secretion by carbon fiber amperometry assay, quantitative methylation-specific PCR, morphologic changes, cell viability, apoptosis activity and the expression levels of phospho-Akt1, Akt1, HIF-1α, PI3K, p21, CAIX, 5-HT, phospho-mTOR, and mTOR in xenografts derived from typical H727 and atypical H720 BC cell lines.
A nationwide study of head and neck cancers in France has revealed that the true burden of the disease is underestimated by at least one-third, and that head and neck cancers carry a very high risk of secondary primary cancers, according to two presentations at the ESMO 2016 Congress in Copenhagen.
Morphotek, Inc., a subsidiary of Eisai Co., Ltd., has announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of therapeutic antibodies to a cancer-associated protein identified by NCI researchers.
› Verified 2 days ago
| Entity Name | Northwest Anesthesia Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770531196 PECOS PAC ID: 3274420138 Enrollment ID: O20040304000014 |
News Archive
Building upon previous work, researchers at the Icahn School of Medicine at Mount Sinai identified cells in the embryos of mice that are precursors to blood stem cells or hematopoietic stem/progenitor cells.
A cross-institutional research group has revealed for the first time in the world that infants with symptomatic congenital cytomegalovirus (CMV) infection who were treated with a combination of immunoglobulin fetal therapy and neonatal therapy with antiviral drugs were less likely to experience the severe aftereffects associated with the infection than those who only received the neonatal therapy.
Oncotarget published "Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis" which reported that microscopic imaging, immunocytochemistry, wound healing assay, caspase-cleaved cytokeratin 18 CytoDeath ELISA assay, immunofluorescence labeling assays for apoptosis, hypoxia, Western Blotting, Tunnel assay, measurement of 5-HT secretion by carbon fiber amperometry assay, quantitative methylation-specific PCR, morphologic changes, cell viability, apoptosis activity and the expression levels of phospho-Akt1, Akt1, HIF-1α, PI3K, p21, CAIX, 5-HT, phospho-mTOR, and mTOR in xenografts derived from typical H727 and atypical H720 BC cell lines.
A nationwide study of head and neck cancers in France has revealed that the true burden of the disease is underestimated by at least one-third, and that head and neck cancers carry a very high risk of secondary primary cancers, according to two presentations at the ESMO 2016 Congress in Copenhagen.
Morphotek, Inc., a subsidiary of Eisai Co., Ltd., has announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of therapeutic antibodies to a cancer-associated protein identified by NCI researchers.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Roger A Coleman, MD P.o. Box 7247, Springfield, OR 97475-0011 Ph: (541) 686-9551 | Dr Roger A Coleman, MD 3333 Riverbend Drive, Springfield, OR 97477-8800 Ph: (541) 222-3154 |
News Archive
Building upon previous work, researchers at the Icahn School of Medicine at Mount Sinai identified cells in the embryos of mice that are precursors to blood stem cells or hematopoietic stem/progenitor cells.
A cross-institutional research group has revealed for the first time in the world that infants with symptomatic congenital cytomegalovirus (CMV) infection who were treated with a combination of immunoglobulin fetal therapy and neonatal therapy with antiviral drugs were less likely to experience the severe aftereffects associated with the infection than those who only received the neonatal therapy.
Oncotarget published "Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis" which reported that microscopic imaging, immunocytochemistry, wound healing assay, caspase-cleaved cytokeratin 18 CytoDeath ELISA assay, immunofluorescence labeling assays for apoptosis, hypoxia, Western Blotting, Tunnel assay, measurement of 5-HT secretion by carbon fiber amperometry assay, quantitative methylation-specific PCR, morphologic changes, cell viability, apoptosis activity and the expression levels of phospho-Akt1, Akt1, HIF-1α, PI3K, p21, CAIX, 5-HT, phospho-mTOR, and mTOR in xenografts derived from typical H727 and atypical H720 BC cell lines.
A nationwide study of head and neck cancers in France has revealed that the true burden of the disease is underestimated by at least one-third, and that head and neck cancers carry a very high risk of secondary primary cancers, according to two presentations at the ESMO 2016 Congress in Copenhagen.
Morphotek, Inc., a subsidiary of Eisai Co., Ltd., has announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of therapeutic antibodies to a cancer-associated protein identified by NCI researchers.
› Verified 2 days ago
Albert R Cho, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3333 Riverbend Dr, Springfield, OR 97477 Phone: 541-686-7300 | |
Mark N Bodily, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 3333 Riverbend Dr, Springfield, OR 97477 Phone: 541-222-3154 | |
Ximeng Yang, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3333 Riverbend Dr, Springfield, OR 97477 Phone: 541-222-3154 Fax: 541-222-3359 | |
Daniel R Hagengruber, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3333 Riverbend Dr, Springfield, OR 97477 Phone: 541-222-3154 | |
Brian P Jones, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3333 Riverbend Dr, Springfield, OR 97477 Phone: 541-222-3154 | |
Dorothy A Penaloza, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3333 Riverbend Drive, Springfield, OR 97477 Phone: 541-222-3154 Fax: 541-222-3359 | |
Christopher B Hagen, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3333 Riverbend Drive, Springfield, OR 97477 Phone: 541-222-3154 Fax: 541-222-3359 |